ADDING HALF POSITION IN CELGENE AT $116.95 (CELG-US)

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

JUSTIFICATION For the last 15 years, Celgene has had an unparalleled record of consistent and growing earnings. Like many of their peers, their valuation has come down due to the public pressure to reduce drug prices. Usually this stock trades around 20 – 25X earnings, we believe that this is an extraordinary company at an attractive entry point (18X earnings). The Purple Chips 12 – 18 month target is $150.00